Navigation Links
Misonix Reports Financial Results for First Half of Fiscal 2013
Date:2/7/2013

months ended December 31, 2012.

For the six months, royalty income received predominantly from Covidien increased 128% to $714,000.

Gross margin for the six months ended December 31, 2012 was 56.9%, primarily attributable to an unfavorable mix of low and high margin product deliveries in addition to the $360,000 amount due to Puricore International Limited under the terms of our contract. Operating expenses for the six month period increased 13% as the Company continued to invest in expanding its sales, marketing and customer support capabilities.

For the six months of fiscal year 2013, the Company reported a net loss of $(609,000), or $(0.09) per diluted share, compared to net income of $136,000, or $0.02 per diluted share, in the six months of fiscal 2012, which included income from discontinued operations ofr $712,000 for the sale of the Company's Laboratory and Forensic Safety Products Business in October 2011.

Michael A. McManus Jr., President and Chief Executive Officer of Misonix, commented, "Top-line results for the first half of fiscal 2013 are solid. Revenue for the six months increased 19%. We are particularly pleased with the 31% increase in international revenue for the first half of the year. We achieved strong revenue growth across our major product lines including BoneScalpel revenue that increased 99% and SonicOne revenue that increased 82%. Sales of our SonaStar product in the first half of 2013 were comparable to those of the same period last year. We are very pleased with the continuing acceptance by the surgical community worldwide of our BoneScalpel and SonicOne products. There were four abstracts submitted on the clinical benefits of using the BoneScalpel in spine surgery and three abstracts with regards to the benefits of utilizing our SonicOne product for wound healing during the first half and second fiscal quarter of 2013 respectively. On a cumulative basis, if we exclude declining revenue from our legacy produ
'/>"/>

SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Misonix Presents at MicroCapClub Invitational
2. Misonix Terminates Distribution Agreement With Aesculap
3. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
4. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
5. Misonix Product Featured At Neurosurgery Congress
6. Misonix Adds 6 Spine Sales Agencies In The U.S.
7. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
8. Misonix Inks New Distribution Agreement For Croatia And Slovenia
9. Misonix And Soelim Create New Distribution Alliance For South Korea
10. Misonix Participates In Cleveland Spine Review
11. Misonix Adds Industry Veteran To Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Mandatory takeover offer for ... or the "Company") is pleased to announce the signing ... Marijan Han žeković to acquire his 63.3% holding ... a Croatian listed pharmaceutical business.   Dechra ... to €51.4 million for the entire share capital on ...
(Date:7/31/2015)... , July 31, 2015  Physicians and ... in the biopharmaceutical market. Patients are better informed ... selecting and switching therapies. This shift in power ... marketers, efforts toward patient-focused marketing. As ... marketers have learned it,s important to educate, communicate ...
(Date:7/31/2015)... July 31, 2015  Seeger Weiss LLP is reporting that ... a warning letter to C.R. Bard, the manufacturer of ... strides to correct violations the agency found at two of ... after the FDA cited them during Inspectional Observations that occurred ... Tempe, AZ , location and on October ...
Breaking Medicine Technology:Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... ADDISON, Texas, March 11, 2011 U LURUInc.(NYSE ... the development of a portfolio of wound management and oral ... NYSE Amex LLC (the "Exchange") advising ULURU that it is ... continued listing standards under Section 1003 of the Exchange,s Company ...
... (Nasdaq: NVAX ), a clinical-stage vaccine company, announced ... be presenting at the ROTH 23rd Annual OC Growth Stock ... at The Ritz Carlton, Laguna Niguel, CA.  A live audio-only ... Company website at www.novavax.com under Investors/Events, and a ...
Cached Medicine Technology:ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex 2
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... They know ... Providence St. Vincent Medical Center offers some of the best care in the ... neurosurgeon and neurointerventionalist, achieved the fastest average blood clot removal time in the country. ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los Angeles ... need. Most people know that general health emergencies, such as broken arms or a ... people know where to turn to during a dental emergency. This is important, because ...
(Date:8/3/2015)... , ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: ... is scheduled to present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 ... webcast and subsequent archived replay of the Company’s presentation may be accessed via the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article ... Stem Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" ... to the report, the new study showed that harvesting stem cell-rich bone marrow from ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... research suggests that the patients who undergo surgery to ... later developing pancreatic cancer. The investigators base their findings ... operation known as gastrectomy to remove their ulcers.// ... the stomach or a portion of the small intestine, ...
... has sex and any subsequent risk of birth defects such ... of sex might increase the risk of birth defects in ... and gynecology at Baylor College of Medicine in Houston told ... known causes of birth defects in lower animals. ...
... The government approved a long-awaited treatment for lymphoma - ... radiation directly to cancer cells. Idec Pharmaceuticals' Zevalin becomes ... US. // ,It's a new approach, adding ... CD20 found on lymphoma cells. The antibodies attach to ...
... group have developed an efficient method of identifying strains ... diseases such as meningococcal disease. The Cooperative ... Technology (QUT) has taken advantage of two new technologies// ... recently - DNA chip technology and comparative gene sequence ...
... which could make gene therapy powerful. The advance which is ... the modified genes to slip right into the cell nucleus.A ... an entire human.// ,This means that the DNA molecule ... smuggle or slip their modified DNA strands into the cells ...
... to a new study, filtering out the antibodies that can ... live donor transplants. Many patients need a kidney transplant but ... Body organs, from dead bodies, are in short supply, and ... must be of a compatible blood group. ,But ...
Cached Medicine News:Health News:Ulcer Surgery connected to danger of Pancreatic Cancer 2Health News:Identifying bacteria made amiable 2
... Plus Dodeca cell accommodates up to 12 ... first-dimension runs in the PROTEAN IEF system, ... format. The PROTEAN Plus Dodeca cell's cooling ... electrodes, allow consistent, high-resolution results. The handcasting ...
... The PROTEAN Plus Dodeca cell accommodates up ... capacity of first-dimension runs in the PROTEAN ... a convenient format. The PROTEAN Plus Dodeca ... its plate electrodes, allow consistent, high-resolution results. ...
... gels run in the specially designed E-Base™ ... power supply in one device. The daughter ... and to other daughter E-Base™ platforms for ... E-Gel® 96 or E-Gel® 48 gels. Note: ...
... E-Gel® 48 gels run in the ... combine the base and power supply ... E-Base™ power supply contains an electrical ... to an electrical outlet and is ...
Medicine Products: